1887

Abstract

SUMMARY

Induction of Epstein–Barr virus antigens in Raji cells by 12--tetradecanoylphorbol 13-acetate (TPA), 5′-iodo-2′-deoxyuridine (IUdR), n-butyric acid (n-BA) antibody to IgM (anti-IgM) and a recently described serum factor was studied after single applications of individual inducers or of their combinations. Whereas individual inducers led to activation only in a limited number of cells, certain combinations of inducers greatly enlarged the reactive cell population. In synergistically acting combinations of drugs, the dose necessary for half-maximal induction of the first inducer was shifted to a much lower value by the second inducer. The serum factor cooperated with any of the four inducers TPA, IUdR, anti-IgM and n-butyric acid, whereas TPA only interacted with IUdR and n-butyric acid. The effects of the serum factor and of TPA showed some similarities but were not identical, whereas IUdR and n-BA showed identical effects.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-64-6-1337
1983-06-01
2024-12-12
Loading full text...

Full text loading...

/deliver/fulltext/jgv/64/6/JV0640061337.html?itemId=/content/journal/jgv/10.1099/0022-1317-64-6-1337&mimeType=html&fmt=ahah

References

  1. Bauer G., Höfler P., Zur Hausen H. 1982a; Epstein-Barr virus induction by a serum factor. I. Induction and cooperation with additional inducers. Virology 121:184–194
    [Google Scholar]
  2. Bauer G., Hofler P., Simon M. 1982b; Epstein-Barr virus induction by a serum factor. II. Purification of a high-molecular weight protein that is responsible for induction. Journal of Biological Chemistry 257:11405–11410
    [Google Scholar]
  3. Bauer G., Höfler P., Simon M. 1982c; Epstein-Barr virus induction by a serum factor. III. Characterization of the purified molecule and the mechanism of its activation. Journal of Biological Chemistry 257:11411–11415
    [Google Scholar]
  4. Crawford D. H., Epstein M. A., Bornkamm G. W., Achong B. G., Finerty S. 1979; Biological and biochemical observations on isolates of EB virus from the malignant epithelial cells of two nasopharyngeal carcinomas. International Journal of Cancer 24:294–302
    [Google Scholar]
  5. Diehl V., Henle G., Henle W., Kohn G. 1969; Effect of a herpes group virus (EBV) on growth of peripheral leukocyte cultures. In vitro 4:92–99
    [Google Scholar]
  6. Epstein M. A., Barr Y. M., Achong B. G. 1965; Studies with Burkitt’s lymphoma. Wistar Institute Symposia Monographs 4:69–82
    [Google Scholar]
  7. Gerber P. 1972; Activation of Epstein-Barr virus by 5-bromodeoxyuridine in ‘virus-free’ human cells. Proceedings of the National Academy of Sciences, U,. S,. A 69:83–85
    [Google Scholar]
  8. Hampar B., Derge J. G., Martos L. M., Walker J. L. 1972; Synthesis of Epstein-Barr virus after activation of the viral genome in a ‘virus-negative’ human lymphoblastoid cell (Raji) made resistant to 5-bromodeoxyuridine. Proceedings of the National Academy of Sciences, U,. S,. A 69:72–82
    [Google Scholar]
  9. Henle G., Henle W. 1966; Immunofluorescence in cells derived from Burkitt’s lymphoma. Journal of Bacteriology 91:1248–1256
    [Google Scholar]
  10. Hinuma Y., Konn M., Yamaguchi J., Wudarski J. D., Blakeslee J. R., Grace J. T. 1967; Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. Journal of Virology 1:1045–1051
    [Google Scholar]
  11. Ito Y., Kawanishi M., Harayama T., Takabayashi S. 1981; Combined effect of the extracts from Croton tiglium, Euphorbia lathyris or Euphorbia tirucallis and n-butyrate on Epstein-Barr virus expression in human lymphoblastoid P3HR-1 and Raji cells. Cancer Letters 12:175–180
    [Google Scholar]
  12. Lenoir G. 1979; Unit of biological carcinogens: laboratory studies. In International Agency for Research on Cancer Annual Report 1979 pp 83–84 Lyon: WHO/IARC;
    [Google Scholar]
  13. Luka J., Kallin B., Klein G. 1979; Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228–231
    [Google Scholar]
  14. Miller G., Lipman M. 1973; Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proceedings of the National Academy of Sciences, U,. S,. A 70:190–194
    [Google Scholar]
  15. Miller G., Cooper D., Niederman J., Pagano J. 1976; Biological properties and viral surface antigens of Burkitt lymphoma- and mononucleosis-derived strains of Epstein-Barr virus released from transformed marmoset cells. Journal of Virology 18:1071–1080
    [Google Scholar]
  16. Pope J. H., Achong B. G., Epstein M. A., Biddulph J. 1967; Burkitt lymphoma in New Guinea: establishment of a line of lymphoblasts in vitro and description of their fine structure. Journal of the National Cancer Institute 39:933–945
    [Google Scholar]
  17. Pulvertaft R. J. V. 1965; A study of malignant tumours in Nigeria by short term tissue culture. Journal of Clinical Pathology 18:261–273
    [Google Scholar]
  18. Tovey M. G., Lenoir G., Begon-Tours J. 1978; Activation of latent Epstein-Barr virus by antibody to human IgM. Nature, London 276:270–272
    [Google Scholar]
  19. Wittmann P., Höfler P., Bauer G. 1982; Epstein-Barr virus induction by a serum factor. IV. Ubiquitous occurrence of the factor within vertebrates and its interaction with defined lymphoid cell lines. International Journal of Cancer 30:503–510
    [Google Scholar]
  20. Yamamoto N., Mueller-Lantzsch N., Zur Hausen H. 1980; Effect of actinomycin D and cycloheximide on Epstein-Barr virus early antigen induction in lymphoblastoid cells. Journal of General Virology 51:255–261
    [Google Scholar]
  21. Zur Hausen H., O’Neill F. J., Freese U. K., Hecker E. 1978; Persisting oncogenic herpesvirus induced by tumour promotor TPA. Nature, London 272:373–375
    [Google Scholar]
  22. Zur Hausen H., Bornkamm G. W., Schmidt R., Hecker E. 1979; Tumour initiators and promotors in the induction of Epstein-Barr virus. Proceedings of the National Academy of Sciences, U,. S,. A 76:782–785
    [Google Scholar]
/content/journal/jgv/10.1099/0022-1317-64-6-1337
Loading
/content/journal/jgv/10.1099/0022-1317-64-6-1337
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error